ReviewBiology methods & protocols2025
Advances and future directions of aptamer-functionalized nanoparticles for point-of-care diseases diagnosis.
Review in Biology methods & protocols, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Aptamers in Ocular Disease Therapy and Drug Delivery: Current Progress and Future Opportunities.Current therapeutic research, clinical and experimental · 2026Review
- Targeted Strategies for Treatment of Colorectal Cancer: Exploring the Use of Aptamers and Gold Nanoparticles.Molecules (Basel, Switzerland) · 2026Review
- CD47 Aptamer-Decorated Fluorescent POSS Hybrid Nanoparticles as a Biohybrid Interface for Probing Prostate Cancer-Macrophage Interactions.Biomimetics (Basel, Switzerland) · 2026Article
- Comparative Materials-Level Evaluation of 3'- and 5'-Thiol DNA Aptamer Conjugation on Gold Nanospheres and Nanoflowers: Apparent DNA Loading Output, Morphology Retention, and Qualitative Salt-Challenge Response.Sensors (Basel, Switzerland) · 2026Article
- UiO-66 metal-organic frameworks in biomedicine: From structural tunability to bioimaging, photodiagnostics, and photodynamic cancer therapy.FEBS open bio · 2026Review
- Nanoparticle Clearance and New Horizons in Engineered Drug Delivery.Pharmaceutics · 2026Review
- Development of an aptamer-based rapid diagnostic assay forMicrobiology spectrum · 2026Article
- Nanomaterials-enabled point-of-care diagnostics for pathogens.Frontiers in medicine · 2026Review
- Advances in the engineering of living probiotics for cancer immunotherapy.Theranostics · 2026Review
- Aptamer-guided RNA nanocarriers for receptor-level targeting of CGRP pathways in chronic migraine.Annals of medicine and surgery (2012) · 2026Article
- Therapeutic Oligonucleotides for Neurodegenerative Diseases: Aptamer Strategies and Clay Nanoparticle-Based Delivery.Chemical record (New York, N.Y.) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Point-of-care (POC) diagnostics have revolutionized disease detection by enabling rapid, on-site testing without the need for centralized laboratory infrastructure. This review presents recent advances in aptamer-functionalized nanoparticles (AFNs) as promising tools for enhancing POC diagnostics, particularly in infectious diseases and cancer. Aptamers, with their high specificity, stability, and modifiability, offer significant advantages over antibodies, while nanoparticles contribute multifunctionality, including signal amplification and targeting capabilities. AFNs have demonstrated up to a 2-10 times increase in detection sensitivity and significant reductions in diagnostic timeframes. We discuss various nanoparticle types, conjugation strategies, real-world applications, and highlight innovative developments such as AI-assisted aptamer design, wearable diagnostic devices, and green nanoparticle synthesis. Challenges related to stability, manufacturing scalability, regulatory hurdles, and clinical translation are critically examined. By merging aptamer precision with nanoparticle versatility, AFNs hold transformative potential to deliver rapid, affordable, and decentralized healthcare solutions, especially in resource-limited settings. Future interdisciplinary research and sustainable practices will be pivotal in translating AFN-based diagnostics from promising prototypes to global healthcare standards.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.